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epidemiology
The crude incidence of breast cancer in the European Union is
109.9/100 000 females per year, the mortality 38.4/100 000
females per year; however, with marked geographical variation.
Incidence is increasing with age and mortality is determined by
initial stage and possibly treatment.
diagnosis
The diagnosis is based on clinical examination, radiological
investigations (bilateral mammography and ultrasound; in
particular casesMRI or other imaging techniquesmay be of value)
and pathomorphological assessment. Pathologic diagnosis with
fine needle aspiration (limited to cases with small nodules or
suspicious areas) or core needle biopsy should be obtained before
any surgical procedure. Final pathological diagnosis should be
made according to the World Health Organization classification
and the tumor–node–metastasis (TNM) (International Union
AgainstCancer andAmerican JointComitteeCancer, sixth edition
2002) staging system analyzing all tissue removed.
staging and risk assessment
In case of preoperative systemic treatment a full clinical staging
should be carried out at the outset. In case of primary surgery
pathologic TNM staging based on hematoxylin and esoin
staining, description of histologic type, standardized grading
and evaluation of resection margins should be reported.
Determination of estrogen receptor (ER) and progesterone
receptor (PgR) status is mandatory, preferably by
immunohistochemistry [III, B]. Reports of
immunohistochemical results for ER and PgR should include
the percentage of ER- and PgR-positive cells.According to the
St Gallen Consensus hormone receptors are no longer included
among the prognostic factors, but are the most relevant
predictive factor for the choice of treatment.
Immunohistochemical determination of HER2 receptor
expression should be performed at the same time for treatment
planning. When semi-quantitative results of
immunohistochemistry are ambiguous (++), in situ
hybridization (FISH or CISH) to determine HER2 gene
amplification should be performed. It is possible to directly
perform a gene amplification study (FISH or CISH) and not
perform the HER2 immunohistochemistry at all.
Routine staging examinations includephysical examination, full
blood counts, routine chemistry including liver enzymes, alkaline
phosphatase, calcium and assessment of menopausal status. This
staging is needed for all patients and it can be acceptable for
patients with small clinical tumors (T1) and without palpable
nodes. For all other cases and in particular for candidates
for pre-operative treatment the conduct of additional
investigations should be considered before rather that after
surgery.
In patients with higher risk (pathological N2 with four or
more positive axillary nodes, or T4 tumors, or with laboratory
signs or clinical signs or symptoms suspicious for the presence
of metastases), chest X-ray, abdominal ultrasound and isotopic
bone scan are appropriate [III, B].
Treatment decisions are based primarily on endocrine
responsiveness of the tumor and secondarily on risk of
recurrence. Risk stratification has been revised and currently
includes three risk groups: low, intermediate and high risk
(Table 1).Vascular invasion has been described as an important
prognostic factor, particularly in node-negative disease.
treatment plan
The multidisciplinary discussion (possibly involving also a
pathologist) leading to treatment planning should be used to
integrate local and systemic therapies aswell as their sequence [III,B].
The possibility of hereditary cancer should be explored and
adequate counseling of relatives evaluated [IV, D].
local therapy
invasive carcinoma
Generally, operable breast cancer is treated initially by surgery,
using breast-conserving surgery or mastectomy, both in
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combination with axillary dissection or a sentinel node biopsy.
Contraindications to breast-conserving surgery include
multicentric tumors, large tumors (>3–4 cm) in small breasts,
possibly retro-areolar localization and tumor-involved margins
after resection. Sentinel node biopsy should only be performed
in centers with documented experience and accuracy. Sentinel
node biopsy should not be performed in case of palpable
axillary node(s), T3 or T4 tumors, multicentric tumors, prior
axillary surgery or large biopsies, after breast reconstruction or
implantation of a prosthesis, during pregnancy or lactation,
and after neoadjuvant systemic treatment outside of clinical
trials. Breast radiotherapy is strongly recommended after
breast-conserving surgery [I, A]. Post-mastectomy radiotherapy
has been recommended for patients with four or more positive
axillary nodes [II, B] and is suggested for T3 tumors
independent of the nodal status [III, B].
ductal carcinoma in situ and lobular carcinoma in
situ
When ductal carcinoma in situ (DCIS) is treated by breast-
conserving surgery, all subgroups of patients benefit from
adjuvant radiation [I, A], while tamoxifen is indicated in
women with ER-positive DCIS [II, B] and its use in patients
with ER-negative disease may be detrimental. Lobular
carcinoma in situ (LCIS) is a risk factor for future development
of invasive cancer. It should be completely resected.
primary systemic therapy
Before primary systemic therapy a biopsy for histology and
analysis of predictive factors should be performed. In addition,
for these higher risk patients full clinical staging to rule out
metastatic disease is necessary. Primary systemic therapy is
indicated for locally advanced breast cancer (stage IIIA, IIIB,
IIIC) [III, B]. It can employ chemotherapy or endocrine
therapy based on predictive factors similar to adjuvant
treatment. If possible it should be followed by both surgery and
radiotherapy and postoperative systemic treatment. Primary
systemic therapy is an alternative for large operable breast
cancer, to allow breast-conserving surgery [I, A].
adjuvant systemic therapy
Treatment decisions are based on two main factors: (i)
estimated endocrine responsiveness of tumor tissue and (ii) risk
of relapse (Table 1). Tumors with a clear or high degree of
expression of ER and/or PgR are considered endocrine
responsive. Patients with a total lack of ER and PgR expression
in their tumors are considered endocrine non-responsive.
Features indicative of uncertainty of endocrine reponsiveness
include low levels of steroid hormone receptor
immunoreactivity (<10% cells positive), lack of PgR, HER2
overexpression and possibly uPA and PAI-1.
Patients with tumors considered endocrine responsive may
receive endocrine treatment alone (Table 2), or a combination
of endocrine and chemotherapy. Patients with tumors of
uncertain endocrine responsiveness are usually treated with
a combination of endocrine and chemotherapy. Patients with
endocrine non-responsive tumors derive greater benefit from
chemotherapy and should not receive endocrine therapy. In
addition to endocrine and chemotherapy, patients with HER2
overexpression or amplification should be considered for
adjuvant treatment with trastuzumab (see below).
For each individual, the choice of adjuvant therapy must take
into account the potential benefits, possible side-effects, and
patient preference. Several decision making tools have been
developed to help doctor–patient communication for adjuvant
treatment decisions. Two popular tools are ‘Adjuvant! Online’
and the National Comprehensive Cancer Network guidelines.
endocrine therapy
Patients with tumors of likely or uncertain endocrine
responsiveness should be treated with endocrine therapy
(Tables 2 and 3).
Table 1. Definition of risk categories for patients with operated breast
cancer
Low risk Node-negative and all of the
following features
d pT £ 2 cm
d Grade 1
d Absence of peritumoral vascular invasion
d HER2 gene neither overexpressed nor amplified
d Age ‡ 35 years
Intermediate risk Node-negative and at least one of the
following features:
d pT > 2 cm
d Grade 2 bis 3
d Presence of peritumoral vascular invasion
d HER2 gene overexpressed or amplified,
d Age < 35 years
d Node-positive (1–3 involved nodes)
d HER2 gene neither overexpressed nor amplified
High risk Node-positive (1–3 involved nodes)
d HER2 gene overexpressed or amplified
d Node-positive (4 or more involved nodes)
Table 2. Choice of treatment modalities
Risk category Endocrine responsiveness
Responsive Uncertain Non-responsive
Low risk ET or nil ET or nil –
Intermediate risk ET alone
or CT/ETa
CT/ETa CT
High risk CT/ETa CT/ETa CT
aWhen combining chemotherapy with tamoxifen, the latter should be
started after the end of chemotherapy (CT/ET) [II, A]. It is unclear
whether aromatase inhibitors should be started concurrently with
chemotherapy (CT + ET) or sequentially after chemotherapy (CT/ET). In
premenopausal patients GnRH analogs can be started concurrently with
chemotherapy, leading to rapid amenorrhea.
ET, endocrine therapy; Nil, no adjuvant systemic therapy; CT,
chemotherapy.
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In premenopausal patients the combination of ovarian
function ablation with tamoxifen, or tamoxifen alone (20 mg/
day for 5 years) is indicated. Bilateral ovarectomy or irradiation
of the ovaries leads to irreversible ablation of ovarian function.
Gonadotropin-releasing hormone analogs (GnRHAs) (e.g.
goserelin 3.6 mg s.c. monthly) generally lead to reversible
ovarian suppression. They should be given for at least 2 years,
but optimal duration for this treatment has not yet been
established [III, D]. The adjuvant use of the combination of
GnRHA and aromatase inhibitors in premenopausal patients is
not currently indicated. The use of aromatase inhibitors alone
must be avoided, as no evidence of efficacy is available.
In postmenopausal patients adjuvant endocrine therapy
should include an aromatase inhibitor at some point in time. It
is as yet undetermined whether aromatase inhibitors should be
used upfront, and for which exact time period. Alternatively,
tamoxifen is still an option, with a planned switch to an
aromatase inhibitor after 2–3 or after 5 years. Adjuvant
aromatase inhibitors increase disease-free survival when
compared with tamoxifen. This has been shown for anastrozole
(1 mg daily for 5 years) and for letrozole (2.5 mg daily for 5
years) given upfront [I, A], for exemestane (25 mg daily) and
for anastrozole (1 mg daily) given after 2–3 years of tamoxifen
[I, A] and for letrozole (2.5 mg daily) and anastrozole
compared with placebo given after 5 years of tamoxifen [I, A].
The long-term cardiovascular and skeletal adverse effects
associated with aromatase inhibitors are an issue of concern.
Women treated with aromatase inhibitors should receive
vitamin D and calcium supplements, while there is no clear
evidence for the use of bisphosphonates in the adjuvant setting
comcomitantly with aromatase inhibitor.
chemotherapy
Adjuvant chemotherapy for intermediate- or high-risk patients
(Tables 1–3) should use a combination regimen (Table 4). In
early 2006 the consensus is that such a combination should
include an anthracycline, and should involve a duration of at
least four cycles of treatment. The use of taxanes may be limited
to high-risk patients, especially if ER-negative where data show
a substantial benefit. Controversial is the use of dose-dense
schedules with prophylactic G-CSF.
trastuzumab
Patients with HER2 overexpression (3+) or HER2 amplification
can benefit from adjuvant treatment with trastuzumab. There is
no evidence for the use of trastuzumab in patients with node-
negative, HER2/neu-positive small (<1 cm) tumors, as in this
group of patients side-effects may override possible benefits.
Based on pharmacokinetic analyses a 3-weekly schedule (6 mg/
kg) is considered equivalent to a weekly schedule (2 mg/kg).
The standard duration of adjuvant trastuzumab has not yet
been established, For the time being 1 year is recommended.
Trastuzumab may be started in parallel with a taxane, but it
should not be given concurrently with an anthracycline. Even
when given after an anthracycline-containing regimen
trastuzumab has cardiotoxic effects and heart function should
be routinely monitored.
follow-up
History taking, eliciting of symptoms and physical examination
every 3–6 months for 3 years, every 6–12 months for 3 years,
then annually [A], with attention being paid to long-term side-
effects, e.g. osteoporosis.
Ipsilateral (after breast-conserving surgery) and contralateral
mammography every 1–2 years [D].
Not routinely recommended for asymptomatic patients:
blood counts, chemistry, chest X-ray, bone scan, liver
ultrasound, CT scans of chest and abdomen and any tumor
markers such as CA 15-3 or CEA [I, A].
note
Levels of evidence [I–V] and grades of recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading
were considered justified standard clinical practice by the
experts and the ESMO faculty.
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